Displaying 105 (all) recruiting clinical trials.
-
A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician s choice chemotherapy compared to trastuzumab in combination with physician s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment
This study tests a new treatment called zanidatamab against a standard treatment called trastuzumab. Both treatments will be given with chemotherapy chosen by the doctor ...
Phase
Interventional
-
An open-label randomized trial of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (BTC)
This study is testing a new treatment called zanidatamab to see how well it works and how safe it is for people with a type ...
Phase
Interventional
-
A Phase III Multi-center Open-label Sponsor-blinded Randomized Study of AZD0901 Monotherapy Compared with Investigator s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is designed to test how effective a new treatment called AZD0901 is for patients with advanced stomach cancer or cancer that is at ...
Phase
Interventional
-
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) - ALXN1210-IgAN-320
We are doing this study to learn more about the study drug, called ravulizumab, which can also be referred to as ALXN1210, and also to ...Phase
Interventional
-
A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
In this study, patients will fill out Health-Related Quality of Life (HRQoL) questionnaires when they visit the hospital for their scheduled appointments. These questionnaires will ...
Phase
Interventional
-
A multicenter randomized double-blind risankizumab-controlled parallel-group study to evaluate the efficacy and safety of bimekizumab in adult study participants with active psoriatic arthritis
The purpose of this research study is to evaluate the efficacy (how well something works) and safety of bimekizumab in study participants with active psoriatic ...Phase
Interventional
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
The purpose of this study is to learn about the safety, effectiveness, and long-term outcomes of the research drug, pegozafermin, for patients with compensated cirrhosis ...Phase
Interventional
-
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)
This is a phase 3 study, comparing the new medicine called Elacestrant (selective estrogen receptor degrader) with standard hormonal treatments in patients with ER-positive/HER2-negative ...
Phase
Interventional
-
AAML1831: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3
This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without ...Phase
Interventional
-
A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292)
This is a Phase Ib/III, multicentre study of capivasertib plus CDK4/6i (palbociclib, ribociclib or abemaciclib) and fulvestrant, for the treatment of participants with ...Phase
Interventional
